Impact of Starting a Dolutegravir-based Regimen on HIV-1 Proviral DNA Reservoir Of Treatment Naïve and Experienced Patients

Inclusion Criteria: * Male or female aged from de 18 to 80 years * Patient starting a DTG-regimen * Patients agreeing to use methods of birthcontrol while on the study and during the 6 weeks after stopping DTG treatment * Signed and dated written informed consent is obtained from the subject or the subject's legal representative prior to screening Exclusion Criteria: * Women who are pregnant or breastfeeding * HBV or HCV coinfection * Participation in another clinical drug or device trial where the last dose of drug was within the past 30 days or an investigational medical device is currently implanted * An active AIDS-defining condition at Screening * Documented resistance to DTG * Allergy or intolerance to the study drugs or their components or drugs of their class * Any acute or verified Grade 4 laboratory abnormality (with the exception of Grade 4 lipids) at Screening. * Coadministration with Dofelitide